Art. -Nr.: HY-B1018A

Phenelzine sulfate

6 Cited Publications

Kundenbewertung

Based on 6 publication(s) in Google Scholar

Phenelzine sulfate, an antidepressant agent, is an irreversible and orally active monoamine oxidase (MAO-A and MAO-B) inhibitor. Phenelzine sulfate inhibits GABA transaminase and primary amine oxidase (PrAO), and sequester reactive aldehydes. Phenelzine sulfate also inhibits LSD1 (Ki: 5.6 μM) and suppresses oxidative stress and lipogenesis. Phenelzine sulfate elevates neurotransmitters (serotonin, norepinephrine, dopamine). Phenelzine sulfate is studied in neurological, metabolic and cancer diseases for depression and anxiety disorders, stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, inflammatory pain, obesity and prostate cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.95%
CAS. Nr.: 156-51-4
Formel: C₈H₁₄N₂O₄S
Molecular Weight:234.27

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Phenelzine sulfate Chemical Structure

CAS. Nr.: 156-51-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (6)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Monoamine Oxidase Isoform-spezifische Produkte anzeigen :

MAO-A
MAO-B

Alle Histone Demethylase Isoform-spezifische Produkte anzeigen :

In Vitro

Phenelzine sulfate inhibits recombinant mouse MAOA/MAOB, PIPOX, PCYOX1, ALDH2 and SCRN3 proteins^[2].
Phenelzine (80 μM; 48 h; H460) sulfate reduces H460 cell proliferation by less than 50% in a [³H]thymidine incorporation assay^[3].
Phenelzine (10-100 μM; 24 h; rat retinal ganglion cells) sulfate reduces 3-Aminopropanal-induced toxicity^[1].
Phenelzine (150-300 nmol; 30 min; phosphate-buffered saline) sulfate reduces acrolein levels in vitro^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

Rat retinal ganglion cells
Concentration:

10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 100 μM
Incubation Time:

24 h
Result:

LDH release was measured 24 hours after cotreatment with 3-Aminopropanal, showing reduced toxicity.

Western Blot Analysis^[3]

Cell Line:

LNCaP
Concentration:

3 μM, 10 μM, 20 μM, 40 μM
Incubation Time:

48 h
Result:

No significant changes in H3K4Me2 or total H3 levels were observed.

Cell Proliferation Assay^[3]

Cell Line:

H460
Concentration:

80 μM
Incubation Time:

48 h
Result:

Less than 50% reduction in 3H-thymidine incorporation.

In Vivo

Phenelzine (31.6 mg/kg; drinking water; once daily; 12 weeks) sulfate exhibits lower body fat content, subcutaneous white adipose tissue (WAT) mass and lipid content in skeletal muscles than control, without decreases body weight gain or food consumption^[4].
Phenelzine (15 mg/kg; IP, 15 minutes post-injury) sulfate reduces acrolein and 4-HNE levels and improves recovery in a rat spinal cord injury (SCI) model^[1].
Phenelzine (aquarium water) sulfate mitigates paraquat-induced neurotoxicity in zebrafish by reducing oxidative stress and preserving dopamine levels and promotes axonal regrowth and remyelination in a zebrafish SCI model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female C57BL/6 micEAE was induced in female C57/BL mice with MOG35-55 (HY-P1240)(subcutaneous injection).^[5]
Dosage:

15 mg/kg
Administration:

IP; daily, for 28 days
Result:

Reduced disease severity in the chronic phase and was associated with substantial improvements in exploratory behavior.
Showed a normalization of 5-HT levels in the ventral horn of the spinal cord that might account for the improvements in behavioral outcomes.

Animal Model:

Rats; traumatic brain injury (TBI) model, induced by controlled cortical impact (CCI-TBI)^[1]
Dosage:

15 mg/kg
Administration:

IP; once; 15 minutes post-injury
Result:

Prevented the decrease in respiratory control ratio, increased cortical tissue sparing from 86 to 97%, and reduced 4-HNE levels in mitochondria.

Animal Model:

Gerbils (male, 8 weeks); global ischemia model, induced by carotid ligation for 5 minutes followed by reperfusion^[1]
Dosage:

15 mg/kg, 30 mg/kg
Administration:

IP; once daily; 6 days
Result:

Significantly attenuated neuronal loss in the hippocampal CA1 region compared to ischemia-vehicle gerbils.

Animal Model:

C57BL/6 mice (male, 9 weeks); no disease model^[4]
Dosage:

31.6 mg/kg
Administration:

Drinking water; once daily; 12 weeks
Result:

Exhibited lower body fat content, subcutaneous WAT mass and lipid content in skeletal muscles than control, without decreased body weight gain or food consumption. Phenelzine impaired the lipogenic but not the antilipolytic actions of insulin in WAT.
Lowered MAO activity and hydrogen peroxide release in WAT.
Decreased phosphoenolpyruvate carboxykinase (PEPCK) expression in subcutaneous WAT.

Animal Model:

C57BL/6 mice (male, 9 weeks); no disease model^[4]
Dosage:

31.6 mg/kg
Administration:

Drinking water; once daily; 12 weeks
Result:

Lowered non-fasting blood glucose levels.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 156-51-4
Appearance Solid
Molecular Weight 234.27
Formel C₈H₁₄N₂O₄S
Color White to off-white
SMILES

NNCCC1=CC=CC=C1.O=S(O)(O)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (6)

All

Sort by:

Journal Impact Factor

Nat Commun

Sleep fragmentation exacerbates myocardial ischemia‒reperfusion injury by promoting copper overload in cardiomyocytes. [Abstract]

2024 May 7;15(1):3834. PMID: 38714741
J Immunother Cancer

Enhancing immunotherapy efficacy in NSCLC through the combined use of phenelzine and Akkermansia muciniphila to regulate gut microbial metabolite 5-HIAA. [Abstract]

2025 Sep 10;13(9):e011831. PMID: 40930748
J Immunother Cancer

Inhibition of stromal MAOA leading activation of WNT5A enhance prostate cancer immunotherapy by involving the transition of cancer-associated fibroblasts. [Abstract]

2025 Mar 22;13(3):e010555. PMID: 40121032
Neurosci Bull

Acrolein Induces Systemic Coagulopathy via Autophagy-dependent Secretion of von Willebrand Factor in Mice after Traumatic Brain Injury. [Abstract]

2021 Aug;37(8):1160-1175. PMID: 33939120
ACS Pharmacol Transl Sci

Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology. [Abstract]

2021 Nov 12;4(6):1818-1834. PMID: 34927013
Front Neurosci

Adhesion Molecule L1 Agonist Mimetics Protect Against the Pesticide Paraquat-Induced Locomotor Deficits and Biochemical Alterations in Zebrafish. [Abstract]

2020 May 28:14:458. PMID: 32547358

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (426.86 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.2686 mL

21.3429 mL

42.6858 mL

5 mM

0.8537 mL

4.2686 mL

8.5372 mL

10 mM

0.4269 mL

2.1343 mL

4.2686 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (8.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (8.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (8.88 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Matveychuk D, et al. Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine. Cell Mol Neurobiol. 2022;42(1):225-242. [Content Brief]

[2]. Bustin KA, et al. Phenelzine-based probes reveal Secernin-3 is involved in thermal nociception. Mol Cell Neurosci. 2023;125:103842. [Content Brief]

[3]. Prusevich P, et al. A selective phenelzine analogue inhibitor of histone demethylase LSD1. ACS Chem Biol. 2014;9(6):1284-1293. [Content Brief]

[4]. Carpéné C, et al. Body fat reduction without cardiovascular changes in mice after oral treatment with the MAO inhibitor phenelzine. Br J Pharmacol. 2018;175(12):2428-2440. [Content Brief]

[5]. Musgrave T, et al. The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain Behav Immun. 2011 Nov;25(8):1677-88. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.2686 mL	21.3429 mL	42.6858 mL	106.7145 mL
	5 mM	0.8537 mL	4.2686 mL	8.5372 mL	21.3429 mL
	10 mM	0.4269 mL	2.1343 mL	4.2686 mL	10.6714 mL
	15 mM	0.2846 mL	1.4229 mL	2.8457 mL	7.1143 mL
	20 mM	0.2134 mL	1.0671 mL	2.1343 mL	5.3357 mL
	25 mM	0.1707 mL	0.8537 mL	1.7074 mL	4.2686 mL
	30 mM	0.1423 mL	0.7114 mL	1.4229 mL	3.5571 mL
	40 mM	0.1067 mL	0.5336 mL	1.0671 mL	2.6679 mL
	50 mM	0.0854 mL	0.4269 mL	0.8537 mL	2.1343 mL
	60 mM	0.0711 mL	0.3557 mL	0.7114 mL	1.7786 mL
	80 mM	0.0534 mL	0.2668 mL	0.5336 mL	1.3339 mL
	100 mM	0.0427 mL	0.2134 mL	0.4269 mL	1.0671 mL

Keywords

Phenelzine sulfate

6 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Phenelzine sulfate

Publications Citing Use of MedChemExpress (MCE) Phenelzine sulfate

Alle Monoamine Oxidase Isoform-spezifische Produkte anzeigen

Alle Histone Demethylase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Phenelzine sulfate Related Classifications

HY-B1018A Related Classifications